August 23, 2017
5 min read
Save

Half of women with early-stage breast cancer consider prophylactic double mastectomy

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Sarah T. Hawley

A quarter of women with early-stage breast cancer and a favorable prognosis strongly considered undergoing contralateral prophylactic mastectomy, according to a study published in Cancer.

Another 29% of women considered the procedure either moderately or weakly, according to researchers.

“We felt it was important to understand the extent to which patients — particularly those with early-stage breast cancer without a genetic mutation or strong risk for contralateral cancer — are considering having this procedure, since that is a necessary step prior to receipt of contralateral prophylactic mastectomy,” Sarah T. Hawley, PhD, MPH, professor of medicine and health management and policy and co-director of center for health communications research at University of Michigan, told HemOnc Today.

A study by Wong and colleagues published earlier this year in Annals of Surgery showed the proportion of women who underwent contralateral prophylactic mastectomy without an elevated risk for developing a second primary cancer was 3.9% in 2002.

The rate has grown to greater than 20% in this population, and contralateral prophylactic mastectomy now represents about half of all mastectomies performed for breast cancer in the United States, according to Hawley and colleagues.

Researchers used the SEER registries of Los Angeles and Georgia to identify 2,578 women treated for early-stage breast cancer in 2013 to 2014. Women completed surveys approximately 7 months after surgery.

After researchers excluded women who reported bilateral disease or who harbored a genetic mutation, the sample size included 2,362 women (median age, 61.8 years; 57.2% white, 18% black, 13.6% Hispanic) from Georgia (53.9%) and Los Angeles (46.1%).

In total, 25% had ductal carcinoma in situ, 47% had stage I disease, 25% had stage II disease, 23% had a first-degree family member with breast cancer, and 71% were not at high risk for a second primary breast cancer.

Fifty-four percent of women had private insurance, 29% had Medicare and 13% had Medicaid.

Consideration of contralateral prophylactic mastectomy — assessed on a 5-point Likert scale — served as the primary outcome. Researchers also assessed the association between patients’ values and decision styles and their strong consideration of the procedure.

Twenty-five percent of women reported strong or very strong consideration of contralateral prophylactic mastectomy, and 29% considered it moderately or weakly.

Researchers noted that decision styles varied. Factors most valued by women at the time of treatment decisions included avoiding worry about recurrence (82%), reducing the need for more surgery (73%), receiving the newest and most advanced treatment (69%), and avoiding treatment side effects (67%).

PAGE BREAK

“We were surprised that one quarter of women considered this procedure, and that another nearly one quarter considered it moderately,” Hawley said. “So, over half of these women are giving contralateral prophylactic mastectomy consideration as part of their initial treatment planning. We were also interested, although not surprised, to learn that both decision styles and values are associated with consideration.”

In a multivariate analysis, women who preferred to make their own decisions, those who valued avoiding worry about recurrence, and those who wanted to avoid radiation appeared significantly more likely to strongly consider contralateral prophylactic mastectomy than women who reported being more logical and those who valued keeping their breast (all, P < .05).

More than half of women surveyed (59%) indicated they wanted their physician to tell them what to do quite or all the time.

Women who had a family history of breast cancer (OR = 2.19; 95% CI, 1.65-2.91) and a larger breast cup size (OR = 1.76; 95% CI, 1.17-2.65) appeared more likely to strongly consider the procedure than their counterparts. Latina women reported strong consideration more often than white women (OR = 2.14; 95% CI, 1.37-3.34), and black women reported strong consideration less often than white women (OR = 0.63; 95% CI, 0.43-0.93).

Many women who undergo contralateral prophylactic mastectomy also opt for breast reconstruction, which can increase the risk for complications, according to Hawley.

“Contralateral prophylactic mastectomy is an extensive procedure relative to the other options, which often include breast conservation,” Hawley said. “With any extensive procedure, there are complication rates that are higher. Recovery time and getting back to normal activities can take longer.”

Researchers noted limitations of their study included a geographical sampling of just two regions, and no information about the availability of breast reconstruction for participants.

Hawley said she hopes her team’s findings shed light on the need for clinicians to have open discussions about treatment options and to better understand their patients’ decision-making tendencies.

“Clinicians need to recognize that many women do consider this procedure,” Hawley said. “Even if the patients do not raise it themselves, they may be thinking about contralateral prophylactic mastectomy. Moreover, their approach to decision-making and values may offer insight into the type of women who may consider this more or less strongly.

“If clinicians could assess these factors in their patients and learn what their values are relative to surgery, it may be possible to have a more patient-centered discussion,” Hawley added. “Ensuring women have an accurate understanding of the risks and benefits also is very important and part of informed decision-making.” – by Chuck Gormley

Reference:

Wong SM, et al. Ann Surg. 2017;doi:10.1097/SLA.0000000000001698.

 For more information:

Sarah T. Hawley, PhD, MPH can be reached at sarahawl@med.umich.edu.

Disclosures: Hawley reports no relevant financial disclosures. Another researcher reports grants from the NIH, the Doris Duke Foundation, and the Greenwall Foundation.